Ryboquin
2013
FOUNDED
PRIVATE
STATUS
Early Stage VC
LATEST DEAL TYPE
$2.34M
LATEST DEAL AMOUNT
6
INVESTORS
Description
Developer of nano-technology and gene therapy designed to treat cancer. The company's nano-technology and gene therapy commercializes human cancer medicines and tumor apoptosis enhancer drug to optimize chemotherapy, enabling patients to access effective oncology therapies.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- Ettrick Riverside, Dunsdale Road
- Scottish Borders
- Selkirk TD7 5EB
- Scotland, United Kingdom
+44 0844 000 0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ryboquin’s full profile, request a free trial.
Ryboquin Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 27-Jul-2017 | $2.34M | 00.000 | 00.000 | Completed | Startup |
| 1. Early Stage VC | 07-Jan-2016 | 00.000 | 00.000 | 00.000 | Completed | Startup |
Ryboquin Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary 1 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
| Ordinary | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Ryboquin Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 19-Jul-2018 | 000000000000000000 | 00.000 | Other Healthcare Technology Systems | 0000 000000 |
Ryboquin Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Brian Kennedy | Angel (individual) | Minority | 000 0000 | 000000 0 | ||
| Brian Souter | Angel (individual) | Minority | 000 0000 | 000000 0 | ||
| Braveheart Investment Group | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Scottish Enterprise | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Strathtay Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Ryboquin Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Alan Walker Ph.D | Chief Executive Officer & Board Member | ||
| David Harrison Ph.D | Non-Executive Director | ||
| Simon Newman Ph.D | Chief Scientific Officer |
Ryboquin Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alan Walker Ph.D | Ryboquin | Chief Executive Officer & Board Member | 000 0000 | |
| Alistair Strachan Ph.D | Self | Board Member | 000 0000 | |
| Brian Kennedy | Ryboquin | Board Member | 000 0000 | |
| Matthew Benson | Self | Non-Executive Director | 000 0000 | |
| Paul Murray | Ryboquin | Non-Executive Chairman | 000 0000 |